News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
585,959 Results
Type
Article (20818)
Company Profile (326)
Press Release (564810)
Multimedia
Podcasts (123)
Webinars (16)
Section
Business (194347)
Career Advice (435)
Deals (29889)
Drug Delivery (66)
Drug Development (71308)
Employer Resources (40)
FDA (12263)
Job Trends (10564)
News (285121)
Policy (22151)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Digital (1)
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (2)
2027 Bio NC Standard (3)
2027 Biotech Bay Elite (4)
2027 Biotech Bay Standard (9)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (6)
2027 Genetown Elite (3)
2027 Genetown Standard (9)
2027 Pharm Country Digital (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (8)
40 Under 40 (1)
Academia (1248)
Accelerated approval (47)
ADA (38)
Adcomms (16)
Allergies (154)
Alliances (41155)
ALS (232)
Alzheimer's disease (1528)
Antibody-drug conjugate (ADC) (607)
Approvals (12938)
Artificial intelligence (648)
ASCO (272)
Autoimmune disease (409)
Automation (41)
Bankruptcy (302)
Belgium (14)
Best Places to Work (8500)
BIO (65)
Biologics (36)
BIOSECURE Act (6)
Biosimilars (195)
BioSpace Insights (89)
Biotechnology (228)
Bispecific (18)
Bladder cancer (180)
Brain cancer (73)
Breast cancer (719)
Cancer (5972)
Cardiovascular disease (439)
Career advice (382)
Career pathing (15)
CAR-T (353)
CDC (9)
CDMO (126)
Celiac Disease (4)
Cell therapy (951)
Cervical cancer (45)
Clinical research (64119)
Collaboration (2189)
Commercialization (31)
Company closure (4)
Compensation (1698)
Complete response letters (78)
COVID-19 (1455)
CRISPR (130)
C-suite (1295)
Cystic fibrosis (151)
Data (8688)
Denatured (28)
Depression (171)
Dermatology (144)
Diabetes (546)
Diagnostics (4910)
Digital health (47)
Diversity (6)
Diversity, equity & inclusion (12)
Drug discovery (383)
Drug pricing (60)
Drug shortages (6)
Duchenne muscular dystrophy (346)
Earnings (80820)
Editorial (38)
Employer branding (6)
Employer resources (38)
Events (104317)
Executive appointments (1041)
Eye disease (7)
FDA (16108)
Fibrodysplasia Ossificans Progressiva (14)
Fragile X (3)
Friedreich's ataxia (26)
Frontotemporal dementia (38)
Funding (1789)
Gene editing (271)
Generative AI (51)
Gene therapy (776)
GLP-1 (718)
Government (1770)
Grass and pollen (4)
Guidances (336)
Healthcare (12077)
Hematology (149)
HIV (73)
Huntington's disease (67)
Idiopathic pulmonary fibrosis (10)
IgA nephropathy (118)
Immunology and inflammation (304)
Immuno-oncology (116)
Indications (231)
Infectious disease (1730)
Inflammatory bowel disease (219)
Inflation Reduction Act (12)
Influenza (98)
Intellectual property (329)
Interviews (58)
IPO (14383)
IRA (13)
Job creations (2423)
Job search strategy (340)
JPM (41)
Kidney cancer (21)
Kidney disease (100)
Labor market (42)
Layoffs (312)
Leadership (21)
Legal (5649)
Licensing (65)
Liver cancer (69)
Longevity (40)
Lung cancer (843)
Lung diease (15)
Lymphoma (424)
Machine learning (49)
Management (10)
Manufacturing (960)
Marketing (19)
MASH (195)
Medical affairs (3)
Medical device (9968)
Medtech (10164)
Mergers & acquisitions (16782)
Metabolic disorders (1330)
mRNA (221)
Multiple sclerosis (170)
Multispecific (4)
NASH (14)
Netherlands (10)
Neurodegenerative disease (473)
Neuropsychiatric disorders (109)
Neuroscience (3180)
Neurotech (2)
NextGen: Class of 2026 (4128)
Non-profit (1520)
Now hiring (47)
Obesity (556)
Opinion (160)
Ovarian cancer (244)
Pain (251)
Pancreatic cancer (354)
Parkinson's disease (399)
Partnered (26)
Patents (647)
Patient advocacy (4)
Patient recruitment (840)
Patient selection (53)
Peanut (58)
People (49918)
Peptides (16)
Pharmaceutical (50)
Pharmacy benefit managers (15)
Phase 1 (21168)
Phase 2 (28934)
Phase 3 (19679)
Pipeline (10898)
Policy (118)
Postmarket research (1891)
Preclinical (9023)
Press Release (52)
Prostate cancer (310)
Psychedelics (84)
Radioligand (2)
Radiopharmaceuticals (374)
Rare diseases (1208)
Real estate (3780)
Recruiting (14)
Regenerative medicine (17)
Regulatory (19892)
Reports (36)
Research institute (1338)
Resumes & cover letters (59)
Rett syndrome (53)
RNA editing (35)
RSV (58)
Schizophrenia (185)
Series A (335)
Series B (232)
Service/supplier (5)
Sickle cell disease (121)
Special edition (23)
Spinal muscular atrophy (148)
Sponsored (24)
Startups (3127)
State (1)
Stem cells (3)
Stomach cancer (8)
Substance use disorders (20)
Supply chain (79)
Tariffs (20)
The Weekly (93)
Vaccines (605)
Venture capital (114)
Weight loss (282)
Wet AMD (3)
Women's health (122)
Worklife (3)
Date
Today (109)
Last 7 days (511)
Last 30 days (2132)
Last 365 days (26143)
2026 (20524)
2025 (25758)
2024 (30028)
2023 (33976)
2022 (43313)
2021 (45731)
2020 (40883)
2019 (29829)
2018 (22460)
2017 (24179)
2016 (22652)
2015 (28865)
2014 (24869)
2013 (20673)
2012 (22487)
2011 (22746)
2010 (22422)
Location
Africa (341)
Alabama (100)
Alaska (3)
Arizona (359)
Arkansas (15)
Asia (29211)
Australia (4494)
California (14629)
Canada (3962)
China (1453)
Colorado (603)
Connecticut (573)
Delaware (393)
Europe (54412)
Florida (2151)
Georgia (442)
Hawaii (4)
Idaho (47)
Illinois (1011)
India (98)
Indiana (465)
Iowa (21)
Japan (603)
Kansas (119)
Kentucky (41)
Louisiana (43)
Maine (38)
Maryland (1527)
Massachusetts (10539)
Michigan (335)
Minnesota (664)
Mississippi (5)
Missouri (98)
Montana (32)
Nebraska (14)
Nevada (148)
New Hampshire (75)
New Jersey (3418)
New Mexico (19)
New York (3593)
North Carolina (1772)
North Dakota (10)
Northern California (7557)
Ohio (370)
Oklahoma (15)
Oregon (35)
Pennsylvania (2816)
Puerto Rico (28)
Rhode Island (39)
South America (528)
South Carolina (83)
South Dakota (1)
Southern California (5841)
Tennessee (157)
Texas (2378)
United States (49383)
Utah (429)
Vermont (1)
Virginia (265)
Washington D.C. (52)
Washington State (1173)
West Virginia (2)
Wisconsin (122)
Wyoming (1)
585,959 Results for "panbela therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
Panbela Announces Transfer to OTCQB Market
Panbela Therapeutics, Inc., a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced that its common stock has been approved for quotation on the OTCQB market.
April 16, 2024
·
7 min read
BioMidwest
Panbela Announces Oral Presentation at Digestive Disease Week (DDW):
Panbela Therapeutics, Inc., a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, announces an oral presentation at the Digestive Disease Week conference, which was held May 18-21, 2024.
June 10, 2024
·
8 min read
Business
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 15, 2024, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2024.
May 1, 2024
·
6 min read
Press Releases
Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.
October 13, 2026
·
4 min read
Business
Panbela Provides Business Update and Reports Q1 2024 Financial Results
Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2024
May 15, 2024
·
13 min read
Drug Development
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
Panbela Therapeutics, Inc. today announced that the independent Data Safety Monitoring Board (DSMB) has completed its third pre-specified safety review of the ongoing Phase 3 ASPIRE clinical trial evaluating ivospemin in combination with gemcitabine and nab-Paclitaxel for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).
June 24, 2024
·
9 min read
BioMidwest
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025Trial’s lower-than-expected event rate suggests improved survival outcomes
Panbela Therapeutics, Inc. today announced that the interim data analysis for its ongoing ASPIRE trial is now expected to be available as soon as Q1 2025.
April 22, 2024
·
8 min read
BioMidwest
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”) today announced that it will host a conference call on March 26, 2024, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023.
March 12, 2024
·
6 min read
BioMidwest
Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024
Panbela Therapeutics, Inc. announced that it will implement the previously announced and stockholder approved 1-for-20 reverse split of its common stock.
January 16, 2024
·
5 min read
Business
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter and full year ended December 31, 2023.
March 26, 2024
·
14 min read
1 of 58,596
Next
